No Trastuzumab Benefit in HER2-Low Breast Cancer After All No Trastuzumab Benefit in HER2-Low Breast Cancer After All
Despite previous analyses suggesting that adding trastuzumab to adjuvant chemotherapy may benefit patients with low HER2 expression, a new large trial shows no impact on outcomes.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Health | Hematology | HER2 | Herceptin